In This Article:
TROP2 Antibody Market USD 3 Billion Opportunity Says Kuick Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global TROP2 Antibody Market, Drug Sales & Clinical Trials Outlook 2028 Report Highlights:
-
Global & Regional TROP2 Antibody Market Sales Insight
-
Global TROP2 Antibody Sales Opportunity: > USD 3 Billion
-
Global TROP2 Antibody Sales Forecast ( 2023 -2028)
-
Approved TROP2 Antibody In Market: 1 Drug (Trodelvy in 2020)
-
Trodelvy Dosage, Price & Sales Insight
-
Trodelvy Global & Regional Sales Insight ( 2020 – 2022)
-
TROP2 Antibody Clinical Pipeline By Company, Indication & Phase
-
Insight On More Than 20 TROP2 Antibodies in Clinical Trials
Download Report:
As technology and research have advanced in recent decades, researchers have learned more about the aberrated cell signaling within a cancer tumor. These cell signals are frequently a source of resistance to treatment and play a critical role in the growth and metastasis of cancer. Therefore, it is essential to target and inhibit these proteins in order to assure a more successful treatment. One such protein that was discovered decades ago but has only lately become relevant for the treatment of cancer is TROP2. More candidates are anticipated to join the clinical and developmental pipelines in the upcoming years as the global clinical pipeline is only moderately populated.
The US FDA approved sacituzumab govitecan-hziy in 2020, making it the first targeted antibody-drug conjugate and TROP2 inhibitor of its kind. Gilead sells it under the brand name Trodelvy. Three additional indications for the medication have been approved since it was first approved for unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), which has aided in growing its patient base. This has resulted in the drug's commercial success, as evidenced by the fact that Trodelvy sales surged by 300% from 2021 to 2022, from US$ 380 Million to US$ 680 Million. Since the US has been making the largest contribution to these yearly sales values, the region’s reputation for accepting innovative medicines has been a major driver of the increase in sales. In addition, the drug is now reimbursed in all significant European pharmaceutical markets, making it available to a lot of patients.
A number of phase 3 clinical trials are evaluating Trodelvy, and in the upcoming years, approvals in other cancer types are anticipated. Other candidates in the global pipeline besides Trodelvy include SKB264, BIO-106, BAT8008, and datopotamab deruxtecan, all of which were developed by prominent pharmaceutical companies like KLUS Pharma, AstraZeneca, Daiichi Sankyo, BiOneCure Therapeutics, and Bio-Thera. Most of these clinical trials are still in their early stages, but so far they have shown encouraging results.